Free Trial
NASDAQ:CLNN

Clene Q1 2024 Earnings Report

Clene logo
$2.62 +0.25 (+10.55%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$2.70 +0.09 (+3.24%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Clene EPS Results

Actual EPS
-$1.80
Consensus EPS
-$1.80
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Clene Revenue Results

Actual Revenue
$0.07 million
Expected Revenue
$0.16 million
Beat/Miss
Missed by -$90.00 thousand
YoY Revenue Growth
N/A

Clene Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Wednesday, May 8, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Clene's Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Clene Earnings Headlines

Elon’s 2025 Silver Crisis (What It Means for You)
Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless production of electric vehicles and solar technology is driving demand for the precious metal to unprecedented levels. Silver—critical for EV batteries, solar panels, and advanced electronics—is now at the center of a supply crisis.
Clene initiated with a Buy at JonesResearch
See More Clene Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Clene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Clene and other key companies, straight to your email.

About Clene

Clene (NASDAQ:CLNN), a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

View Clene Profile

More Earnings Resources from MarketBeat